The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Adult Non-Hodgkin Lymphoma Treatment Market Research Report 2024

Global Adult Non-Hodgkin Lymphoma Treatment Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1745728

No of Pages : 92

Ask Your Query

Synopsis
Non-Hodgkin lymphoma (NHL) is an umbrella term for a group of independent diseases with strong heterogeneity

Global Adult Non-Hodgkin Lymphoma Treatment market is projected to reach US$ 13370 million in 2029, increasing from US$ 7600 million in 2022, with the CAGR of 8.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adult Non-Hodgkin Lymphoma Treatment market research.

Key manufacturers engaged in the Adult Non-Hodgkin Lymphoma Treatment industry include Janssen Pharma, Genentech, Inc., CELGENE CORPORATION, Merck & Co.,Inc., Kyowa Kirin Co., Ltd., AbbVie Inc., Sanofi, Takeda Pharmaceutical Company and AstraZeneca, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Adult Non-Hodgkin Lymphoma Treatment were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Adult Non-Hodgkin Lymphoma Treatment market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adult Non-Hodgkin Lymphoma Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Janssen Pharma
  • Genentech, Inc.
  • CELGENE CORPORATION
  • Merck & Co.,Inc.
  • Kyowa Kirin Co., Ltd.
  • AbbVie Inc.
  • Sanofi
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • Bayer AGNovartis AG
  • Kite Pharma, Inc
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical lndustries Ltd.
  • Bristol Myers Squibb Company

Segment by Type

  • B Cell
  • T Cell
  • NK/T Cells

Segment by Application

  • Hospital
  • Clinic

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Adult Non-Hodgkin Lymphoma Treatment report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Adult Non-Hodgkin Lymphoma Treatment Market Overview
1.1 Product Overview and Scope of Adult Non-Hodgkin Lymphoma Treatment
1.2 Adult Non-Hodgkin Lymphoma Treatment Segment by Type
1.2.1 Global Adult Non-Hodgkin Lymphoma Treatment Market Value Comparison by Type (2023-2029)
1.2.2 B Cell
1.2.3 T Cell
1.2.4 NK/T Cells
1.3 Adult Non-Hodgkin Lymphoma Treatment Segment by Application
1.3.1 Global Adult Non-Hodgkin Lymphoma Treatment Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Adult Non-Hodgkin Lymphoma Treatment Market Size Estimates and Forecasts
1.4.1 Global Adult Non-Hodgkin Lymphoma Treatment Revenue 2018-2029
1.4.2 Global Adult Non-Hodgkin Lymphoma Treatment Sales 2018-2029
1.4.3 Global Adult Non-Hodgkin Lymphoma Treatment Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Adult Non-Hodgkin Lymphoma Treatment Market Competition by Manufacturers
2.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Manufacturers (2018-2023)
2.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Adult Non-Hodgkin Lymphoma Treatment Average Price by Manufacturers (2018-2023)
2.4 Global Adult Non-Hodgkin Lymphoma Treatment Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Adult Non-Hodgkin Lymphoma Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adult Non-Hodgkin Lymphoma Treatment, Product Type & Application
2.7 Adult Non-Hodgkin Lymphoma Treatment Market Competitive Situation and Trends
2.7.1 Adult Non-Hodgkin Lymphoma Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adult Non-Hodgkin Lymphoma Treatment Players Market Share by Revenue
2.7.3 Global Adult Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adult Non-Hodgkin Lymphoma Treatment Retrospective Market Scenario by Region
3.1 Global Adult Non-Hodgkin Lymphoma Treatment Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Adult Non-Hodgkin Lymphoma Treatment Global Adult Non-Hodgkin Lymphoma Treatment Sales by Region: 2018-2029
3.2.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Region: 2018-2023
3.2.2 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Region: 2024-2029
3.3 Global Adult Non-Hodgkin Lymphoma Treatment Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Region: 2018-2029
3.3.1 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Region: 2018-2023
3.3.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Region: 2024-2029
3.4 North America Adult Non-Hodgkin Lymphoma Treatment Market Facts & Figures by Country
3.4.1 North America Adult Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2029)
3.4.3 North America Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adult Non-Hodgkin Lymphoma Treatment Market Facts & Figures by Country
3.5.1 Europe Adult Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2029)
3.5.3 Europe Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adult Non-Hodgkin Lymphoma Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Adult Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2029)
3.6.3 Asia Pacific Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adult Non-Hodgkin Lymphoma Treatment Market Facts & Figures by Country
3.7.1 Latin America Adult Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2029)
3.7.3 Latin America Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adult Non-Hodgkin Lymphoma Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Adult Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Adult Non-Hodgkin Lymphoma Treatment Sales by Country (2018-2029)
3.8.3 Middle East and Africa Adult Non-Hodgkin Lymphoma Treatment Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2018-2029)
4.1.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2018-2023)
4.1.2 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Type (2024-2029)
4.1.3 Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Type (2018-2029)
4.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Type (2018-2029)
4.2.1 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Type (2018-2023)
4.2.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Type (2024-2029)
4.2.3 Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2018-2029)
4.3 Global Adult Non-Hodgkin Lymphoma Treatment Price by Type (2018-2029)
5 Segment by Application
5.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2018-2029)
5.1.1 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2018-2023)
5.1.2 Global Adult Non-Hodgkin Lymphoma Treatment Sales by Application (2024-2029)
5.1.3 Global Adult Non-Hodgkin Lymphoma Treatment Sales Market Share by Application (2018-2029)
5.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Application (2018-2029)
5.2.1 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Application (2018-2023)
5.2.2 Global Adult Non-Hodgkin Lymphoma Treatment Revenue by Application (2024-2029)
5.2.3 Global Adult Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2018-2029)
5.3 Global Adult Non-Hodgkin Lymphoma Treatment Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Janssen Pharma
6.1.1 Janssen Pharma Corporation Information
6.1.2 Janssen Pharma Description and Business Overview
6.1.3 Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Janssen Pharma Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.1.5 Janssen Pharma Recent Developments/Updates
6.2 Genentech, Inc.
6.2.1 Genentech, Inc. Corporation Information
6.2.2 Genentech, Inc. Description and Business Overview
6.2.3 Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Genentech, Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.2.5 Genentech, Inc. Recent Developments/Updates
6.3 CELGENE CORPORATION
6.3.1 CELGENE CORPORATION Corporation Information
6.3.2 CELGENE CORPORATION Description and Business Overview
6.3.3 CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.3.4 CELGENE CORPORATION Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.3.5 CELGENE CORPORATION Recent Developments/Updates
6.4 Merck & Co.,Inc.
6.4.1 Merck & Co.,Inc. Corporation Information
6.4.2 Merck & Co.,Inc. Description and Business Overview
6.4.3 Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck & Co.,Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.4.5 Merck & Co.,Inc. Recent Developments/Updates
6.5 Kyowa Kirin Co., Ltd.
6.5.1 Kyowa Kirin Co., Ltd. Corporation Information
6.5.2 Kyowa Kirin Co., Ltd. Description and Business Overview
6.5.3 Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Kyowa Kirin Co., Ltd. Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.5.5 Kyowa Kirin Co., Ltd. Recent Developments/Updates
6.6 AbbVie Inc.
6.6.1 AbbVie Inc. Corporation Information
6.6.2 AbbVie Inc. Description and Business Overview
6.6.3 AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.6.4 AbbVie Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.6.5 AbbVie Inc. Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Takeda Pharmaceutical Company
6.8.1 Takeda Pharmaceutical Company Corporation Information
6.8.2 Takeda Pharmaceutical Company Description and Business Overview
6.8.3 Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Takeda Pharmaceutical Company Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.8.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AstraZeneca Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Bayer AGNovartis AG
6.10.1 Bayer AGNovartis AG Corporation Information
6.10.2 Bayer AGNovartis AG Description and Business Overview
6.10.3 Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bayer AGNovartis AG Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.10.5 Bayer AGNovartis AG Recent Developments/Updates
6.11 Kite Pharma, Inc
6.11.1 Kite Pharma, Inc Corporation Information
6.11.2 Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Description and Business Overview
6.11.3 Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Kite Pharma, Inc Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.11.5 Kite Pharma, Inc Recent Developments/Updates
6.12 Spectrum Pharmaceuticals, Inc.
6.12.1 Spectrum Pharmaceuticals, Inc. Corporation Information
6.12.2 Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Description and Business Overview
6.12.3 Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Spectrum Pharmaceuticals, Inc. Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.12.5 Spectrum Pharmaceuticals, Inc. Recent Developments/Updates
6.13 Teva Pharmaceutical lndustries Ltd.
6.13.1 Teva Pharmaceutical lndustries Ltd. Corporation Information
6.13.2 Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Description and Business Overview
6.13.3 Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Teva Pharmaceutical lndustries Ltd. Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.13.5 Teva Pharmaceutical lndustries Ltd. Recent Developments/Updates
6.14 Bristol Myers Squibb Company
6.14.1 Bristol Myers Squibb Company Corporation Information
6.14.2 Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Description and Business Overview
6.14.3 Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bristol Myers Squibb Company Adult Non-Hodgkin Lymphoma Treatment Product Portfolio
6.14.5 Bristol Myers Squibb Company Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adult Non-Hodgkin Lymphoma Treatment Industry Chain Analysis
7.2 Adult Non-Hodgkin Lymphoma Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adult Non-Hodgkin Lymphoma Treatment Production Mode & Process
7.4 Adult Non-Hodgkin Lymphoma Treatment Sales and Marketing
7.4.1 Adult Non-Hodgkin Lymphoma Treatment Sales Channels
7.4.2 Adult Non-Hodgkin Lymphoma Treatment Distributors
7.5 Adult Non-Hodgkin Lymphoma Treatment Customers
8 Adult Non-Hodgkin Lymphoma Treatment Market Dynamics
8.1 Adult Non-Hodgkin Lymphoma Treatment Industry Trends
8.2 Adult Non-Hodgkin Lymphoma Treatment Market Drivers
8.3 Adult Non-Hodgkin Lymphoma Treatment Market Challenges
8.4 Adult Non-Hodgkin Lymphoma Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock